Please login to the form below

Not currently logged in
Email:
Password:

neurogenics

This page shows the latest neurogenics news and features for those working in and with pharma, biotech and healthcare.

Merck buys cough drug developer Afferent for $1.25bn

Merck buys cough drug developer Afferent for $1.25bn

Gains access to pipeline with potential for development in ‘neurogenic’ indications. ... These receptors seem to become more common after nerve injury or inflammation, and drugs that block them are thought to have potential in a broad range of

Latest news

  • Lundbeck agrees $658m deal to buy Chelsea Therapeutics Lundbeck agrees $658m deal to buy Chelsea Therapeutics

    Chelsea's marketed product - Northera (droxidopa) - was given a green light by the US FDA in February as the first drug specifically approved to treat symptomatic neurogenic orthostatic hypotension (NOH), a

  • FDA approves Chelsea's rare blood pressure drug FDA approves Chelsea's rare blood pressure drug

    The Food and Drug Administration (FDA) backed Northera capsules (droxidopa) to treat neurogenic orthostatic hypotension (NOH), a chronic drop in blood pressure that is found in patients with Parkinson's disease, ... People with neurogenic orthostatic

  • FDA panel backs Chelsea's Northera for rare disease FDA panel backs Chelsea's Northera for rare disease

    The regulator's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 16 to 1 in favour of the approval of Northera (droxidopa) to treat symptomatic neurogenic orthostatic hypotension (nOH) in patients ... with an underlying neurogenic disorder,

  • Positive opinion for Allergan's NDO treatment

    A positive opinion is given from the Irish Medicines Board for BOTOX treatment for neurogenic detrusor overactivity (NDO). ... NDO results from neurogenic bladder, due to stable sub-cervical spinal cord injury (SCI) or multiple sclerosis (MS).

  • Allergan in $600m Botox settlement

    The company is currently conducting phase II clinical trials as part of an effort to win marketing approval for neurogenic and idiopathic overactive bladder.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch June 2016 Deal Watch June 2016

    in development for the treatment of neurogenic conditions, such as chronic cough.

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    825. Chelsea Therapeutics/ Lundbeck. Company acquisition. Includes Northera (droxidopa) for neurogenic orthostatic hypotension (approved).

  • Pharma deals during May 2014 Pharma deals during May 2014

    Chelsea has the recently FDA-approved droxidopa, the first and only symptomatic treatment for neurogenic orthostatic hypotension ready for launch later this year.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics